Two novel fusion proteins, HCB101 and HCB301, have demonstrated a reduced propensity to cause hematological toxicities in patients with heavily pre-treated solid tumors, according to results presented at the ESMO TAT Asia 2026 conference. By targeting the CD47-SIRPα axis, these agents aim to overcome the treatment-limiting cytopenias—such as anemia and thrombocytopenia—that have historically hindered the development of CD47-directed therapies.
How do HCB101 and HCB301 reduce toxicities?
The primary hurdle in CD47-SIRPα research has been the high incidence of profound cytopenias. Dr. Emanuela Romano of Institut Curie notes that previous agents often reached dose-limiting toxicities that interrupted treatment. HCB101 and HCB301 were specifically engineered to minimize these hematological side effects while maintaining antitumor efficacy.
In the clinical trial for HCB101 (Abstract 63O), researchers found that the maximum tolerated dose was not reached even at 36 mg/kg. While two dose-limiting toxicities were reported—grade 3 and grade 4 thrombocytopenia—there were no instances of bleeding or cumulative anemia. This suggests a more favorable safety profile compared to earlier generations of CD47 inhibitors, which often struggled with cumulative hematological signals.
Did you know? Sustained occupancy of CD47 receptors at or above 90% appears to be a biological threshold for clinical response. In the HCB101 study, patients receiving doses of 8 mg/kg or higher consistently reached this occupancy level, correlating with observed partial responses in head and neck squamous cell carcinoma and marginal zone lymphoma.
What is the clinical outlook for multi-target fusion proteins?
Beyond simple inhibition, the field is shifting toward tri-specific designs. HCB301, a tri-specific fusion protein targeting SIRPα, PD-L1, and TGFβ, showed evidence of manageable safety and disease stabilization in early-phase testing (Abstract 64O). This multi-pronged approach attempts to coordinate immune modulation across three distinct pathways simultaneously.
This trend toward combination or multi-target design is supported by other recent data. For instance, the bispecific antibody NI-1801, which targets CD47 and mesothelin, demonstrated encouraging activity when paired with pembrolizumab in platinum-resistant ovarian cancer patients, according to data reported in Annals of Oncology (2025). Similarly, evorpacept has shown promise in HER2-positive metastatic breast cancer when combined with the dual HER2-targeting agent zanidatamab (ESMO Breast Cancer 2026, Abstract 72P).
Comparing traditional CD47 inhibitors and new fusion agents
The following table illustrates the shift in strategy within the oncology pipeline based on recent clinical findings:
| Agent Type | Primary Limitation | Recent Development |
|---|---|---|
| First-gen CD47 inhibitors | Profound cytopenias | High discontinuation rates |
| HCB101 (Fusion Protein) | Manageable toxicity | No cumulative anemia signals |
| Tri-specifics (e.g., HCB301) | Complex manufacturing | Coordinated immune modulation |
Pro Tip: When evaluating new immunotherapy trials, pay close attention to “cumulative” toxicity reports rather than just single-dose incidents. The lack of cumulative signals in HCB101 trials is a significant indicator of potential long-term patient tolerance.
Frequently Asked Questions
- What are the most common side effects of CD47-SIRPα inhibitors?
Historically, the most common dose-limiting toxicities are cytopenias, specifically anemia and thrombocytopenia. - Why is the CD47-SIRPα axis a target for solid tumors?
CD47 acts as a “don’t eat me” signal on tumor cells; blocking this axis allows the immune system, particularly macrophages, to identify and destroy cancer cells. - Are these new fusion proteins currently available for standard care?
No. HCB101 and HCB301 are currently in early-phase clinical trials and are not yet approved for general clinical use.
Are you tracking the latest in immuno-oncology? Subscribe to our clinical research newsletter to receive updates on phase I and II oncology trial results as they are published.
